SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto Inc. ($GLTO) is trending due to a massive pre-market price surge with significant volume, reminiscent of other recent low-float runners. The community is actively discussing potential price targets and whether it can maintain its momentum, while some express skepticism about the lack of news driving the surge. Traders are closely watching for potential pullbacks or further breakouts as volatility remains high.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing volatility, with community members debating whether it will continue to drop or if a "V"-shaped recovery is imminent. Concerns about an AI bubble and its potential impact on the market are circulating, alongside discussions of possible market manipulation and reactions to economic data. Some traders are taking profits and considering short positions, while others are buying the dip in anticipation of a rebound.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending amid discussions of potential short squeezes and its struggle to break resistance, with community members debating its near-term trajectory. Bullish arguments center on institutional adoption via staking ETFs and upcoming network upgrades, while bears point to historical patterns and potential pullbacks. The conversation also touches on Ethereum's role in tokenization and its relationship with other cryptocurrencies like Bitcoin.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NuCana ($NCNA) is trending as investors discuss its low float, recent Nasdaq compliance, and upcoming presentation at ESMO in October, with some drawing parallels to previous low-float runners like $SPRB. Community members are speculating on a potential short squeeze and anticipating news, while highlighting the company's cash runway into 2029.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

$TMC is trending as the deep-sea mining sector gains traction, with community members discussing potential short squeezes and a possible breakout. Optimism is fueled by anticipation of government partnerships and regulatory approvals, particularly the NOAA decision. Bullish investors are focused on the company's long-term potential in the critical minerals market.

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

Trilogy Metals is trending after the U.S. government announced a major investment, acquiring a 10% stake to support mining exploration in Alaska. The community is actively discussing the potential for a short squeeze and a run to double-digit prices, though some caution against a potential sell-off. This news comes amid a broader push to bolster domestic mineral resources.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as community members assess the stock's performance following recent financial guidance and earnings. Despite increased long-term revenue and EPS growth forecasts driven by AI infrastructure demand, some are concerned about profit margins and the stock's reaction. Discussions include whether the positive outlook justifies the current stock price and comparing Dell's potential with other AI-related stocks.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending as investors are discussing its potential in Bitcoin mining and AI, fueled by news of increased Bitcoin production and a partnership with Bell Canada for AI infrastructure. Community members highlight the company's strong assets, balance sheet, and potential for growth in the HPC and Bitcoin mining sectors. Bullish sentiment is building, with some anticipating a significant price increase in the coming months.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending as shareholders recently approved its business combination with Terra Innovatum, sparking community discussion around the new ticker $NKLR and the timing of its debut. Community members are actively monitoring the ticker change and anticipating potential volatility, with some citing the company's positioning in the nuclear energy sector as a reason for optimism. With the merger approved, the focus now shifts to the execution of Terra Innovatum's plans and its impact on the stock's future performance.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing active discussion around AI's influence and potential overextension, with some traders pointing to Oracle's recent data as a sign of hype while others cite new deals with AMD, Nvidia, and OpenAI as bullish catalysts. Community members are debating the sustainability of the rally and the impact of the government shutdown, with a focus on technical levels and potential pullbacks. Recent price action and analyst targets continue to fuel both bullish and bearish perspectives.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know 

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

<a href="https://stocktwits.com/symbol/TIL">Instil Bio’s stock</a> surged over 25% on Tuesday to levels last seen in early December after Jefferies upgraded the&nbsp;shares to ‘Buy’ from ‘Hold,’ with a new price target of $52 — more than double its current level.&nbsp;The upgrade reflects Jefferies’ confidence in the potential of Instil’s lead asset, SYN-2510, a novel PD-L1xVEGF bispecific antibody targeting multiple solid tumor cancers.Jefferies highlighted SYN-2510 as an “early mover” in the competitive cancer drug space, with significant upside expected from its planned clinical trials.&nbsp;A U.S. Phase 1b/2 study in non-small cell lung cancer (NSCLC) is scheduled to begin in the second half of 2025, focusing on driver gene mutation-negative non-squamous and squamous NSCLC patients.&nbsp;This trial will explore SYN-2510 in combination with chemotherapy, a promising strategy in frontline treatment settings.SYN-2510 is part of a global registrational strategy with China’s ImmuneOnco Biopharmaceuticals.&nbsp;In late 2024, ImmuneOnco started a Phase 1b/2 chemo combination study in China for frontline NSCLC. The collaboration aims to generate clinical proof-of-concept data in multiple solid tumors, with updates anticipated in early 2025.&nbsp;If successful, both companies may initiate joint randomized Phase 3 chemotherapy combination trials for NSCLC and triple-negative breast cancer (TNBC) in 2025.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TIL_sentiment_and_message_volume_Jan_7_premarket_960267c1cd.png" alt="TIL sentiment and message volume Jan 7 premarket.png" width="1318" height="324"><figcaption>TIL sentiment and message volume Jan 7 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits reacted positively, pushing sentiment to ‘extremely bullish’ and boosting its message volume.&nbsp;<stembedurl>https://stocktwits.com/Blackcoupe369/message/599159968</stembedurl>Jefferies also noted that the stock is trading at cash value, which, combined with SYN-2510’s potential, suggests substantial growth opportunities.Instil reported $122.9 million in cash reserves as of September 2024, saying it was sufficient to fund its operations through at least 2026.&nbsp;The stock has climbed over 240% in the past year, driven by optimism around its innovative cancer therapies and impending trials, making it a standout player in the small-cap oncology space.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant

Jefferies highlighted SYN-2510 as an “early mover” in the competitive cancer drug space, with significant upside expected from its planned clinical trials.

Equity

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Shares of Instil Bio Inc. (TIL) skyrocketed over 60% on Friday, placing it among the top five gainers on U.S. stock exchanges and one of the top 20 trending tickers on Stocktwits, where message volume jumped 340%.The surge came after Baird raised its price target on the stock to $180, implying a 146% upside, while maintaining an ‘Outperform’ rating.Baird’s optimism is growing enthusiasm for Instil’s PD-L1xVEGF bispecific antibody, driven by positive data from peers like Akeso’s ivonescimab and Summit’s BNT327 in the same space.Analysts noted recent results and data released ahead of the European Society for Medical Oncology (ESMO) meeting have increased faith in this drug class for treating cancers like triple-negative breast, RCC, and head and neck.Baird expects continued momentum in this therapeutic area at ESMO, seeing further growth opportunities for Instil Bio. Despite the recent rally, the brokerage believes the stock remains undervalued, suggesting more room for gains.Baird’s price target hike follows H.C. Wainwright’s upgrade a day earlier, when it raised its price target from $25 to $40 with a ‘Buy’ rating. Wainwright expressed increased confidence in Instil’s SYN-2510, highlighting its strong antitumor synergy compared to traditional VEGF blockers and PD-L1 antibodies.Instil also announced a restructuring plan last week, including shutting down operations in Manchester, U.K., and laying off its remaining workforce there. The restructuring will cost up to $5.5 million, including $2.2 million in asset impairments and $2 million in severance.<figure class="image"><a href="https://stocktwits.com/symbol/TIL"><img style="aspect-ratio:1320/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TIL_sentiment_and_message_volume_Sep_13_0d4fea2fed.png" alt="TIL sentiment and message volume Sep 13.png" width="1320" height="324"></a><figcaption>TIL sentiment and message volume Sep 13</figcaption></figure>Despite bullish analyst notes, retail investors remain wary. Sentiment on Stocktwits is ‘extremely bearish,’ with users questioning the sustainability of the stock’s rapid ascent.“$TIL 13$ last week, now 77$,” noted one user.<stembedurl>https://stocktwits.com/patbourque/message/585998096</stembedurl>Another warned, “$TIL from $9 to $70 in a few days!!! This is not going to go well next week.”<stembedurl>https://stocktwits.com/ProBulish/message/585995548</stembedurl>Adding to concerns, Instil’s fundamentals look shaky. The company reported zero revenue in the latest quarter, only $6.78 million in cash, and holds a $52.1 million mortgage construction loan on its Tarzana, California property, with an option to draw an additional $32.9 million.Instil Bio has soared 624% in the last month, and retail investors are exercising caution for now.Read next: <a href="https://stocktwits.com/news/markets/equity/mstr-stock-rises-on-bitcoin-buy-retail-bullish/c7z62Y5R5B">MicroStrategy Stock Surges On $1B Bitcoin Buy Amid Crypto Dip: Retail Bulls Rejoice</a> &nbsp;

Instil Bio Soars On Baird’s Price Target Boost: Retail Remains On Sidelines Amid Wild Surge

Despite a recent rally in Instil Bio shares, Baird believes the stock remains undervalued, suggesting more room for gains.

Instil Bio Non-GAAP EPS of -$1.26 beats by $2.14

Instil Bio Non-GAAP EPS of -$1.26 beats by $2.14...

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Current Price	$17.87
Prev Close	$18.43
Open	$18.35
Dividend Yield	0.00%
50-Day Moving Average	$24.45
Beta	1.72
Avg. Volume	187,650.67
PE Ratio	-1.43

52-Week High	$45.07
52-Week Low	$10.80
Market Capitalization	$124.42M
EPS (Annual)	-$11.39
Price to Book	0.94
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TIL Instil Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TIL News